NY-CURIA
13.7.2021 13:32:05 CEST | Business Wire | Press release
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced it has entered into a definitive agreement to acquire Integrity Bio, Inc., a privately held formulation and fill-finish organization headquartered in Camarillo, California.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713005391/en/
Integrity Bio is known in the biopharmaceutical industry as experts in hard-to-formulate biologics and fill-finish of unique therapies in preclinical and clinical development. In a typical year, the organization formulates more than 60 large molecules including proteins, antibodies, lipid nanoparticles, peptides and vaccines in liquid and lyophilized form. The company recently expanded its facilities to include a second state-of-the-art fill-finish line, which more than doubled its manufacturing capacity. Integrity Bio’s customers range from global Fortune 500 companies to small virtual startups.
Integrity Bio’s biologic capabilities are complementary with Curia’s existing business and will enable Curia to expand its ability to meet customers’ needs. Curia currently provides customers with integrated solutions from formulation development through fill-finish commercial manufacturing across three center-of-excellence facilities in Albuquerque, New Mexico; Burlington, Massachusetts and Glasgow, Scotland.
“Curia has decades of experience in managing complexity from R&D through manufacturing,” said Curia Chairman and CEO John Ratliff. “I’m looking forward to welcoming the Integrity Bio team. The addition of Integrity Bio is a great fit with our growth strategy and our existing expertise, enhancing our biologics drug product formulation development as well as our fill-finish network. Integrity Bio also adds West Coast coverage to Curia’s East Coast and European capabilities. Together, we can make an even bigger impact on patients’ lives.”
“We are very excited about this transaction; the strategic fit is sound,” said Michael Reilly, CEO of Integrity Bio. “As part of Curia, we can now offer our customers not only world-class formulation and fill-finish but also world-class commercial manufacturing.”
The transaction, which is subject to standard and customary closing conditions, is expected to close in the third quarter. Terms of the agreement have not been disclosed.
About Curia
Curia, formerly AMRI, is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s 3,100 employees at 21 locations across the U.S., Europe and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com .
About Integrity Bio
Integrity Bio is a privately owned company focused on providing large molecule formulation and fill/finish services to the biotech and pharmaceutical industries. The organization is known for overcoming challenges associated with biologic formulations and for accommodating unique manufacturing requirements for preclinical and clinical development. For more information, please visit IntegrityBio.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005391/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock20.4.2026 01:07:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the underwriters a 45-day option to purchase up to an additional 465,000 shares of the Company’s common stock. The offering is expected to close on or about April 21, 2026, subject to customary closing conditions. The Company is not selling any shares of its common stock in the offering. The Selling Stockholder will receive all of the proceeds from the offering. Maxim Group LLC is acting as the sole book-running manager and Roth Capital Partners is acting as the co-manager for the offering. The offering is being made pursuant to the Com
Horse Powertrain Reveals X-Range C15 Direct Drive Powertrain for Hybridizing BEV Platforms20.4.2026 01:01:00 CEST | Press release
Horse Powertrain, a global leader in innovative and low-emission powertrain systems, will unveil a new ‘all-in-one’ powertrain at Beijing Auto Show 2026: the X-Range C15 Direct Drive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419640202/en/ Left-facing view of the HORSE X-Range C15 Direct Drive The ultra-compact X-Range C15 Direct Drive integrates a full hybrid powertrain – including a 4-cylinder engine, transmission, power electronics, and an electric motor – into a single compact unit with a shared housing, designed to mount to the rear subframe enabling a double isolated installation for best NVH. The X-Range C15 Direct Drive is designed as an ‘all-in-one’ powertrain to replace the rear electric drive unit of an existing BEV platform. It enables an automaker to use a single shared platform for their BEV, HEV, PHEV, and REEV lineups without any significant changes to vehicle design or production environments. The ne
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that
2026 NAB Show Opens Tomorrow, Uniting Global Media Leaders to Shape the Future of Storytelling18.4.2026 04:08:00 CEST | Press release
CEO of Zhong, one of YouTube’s most-watched creators with 70 million subscribers and 95 million followers on all platforms, joins program The 2026 NAB Show kicks off Saturday, April 18, with the show floor and exhibits opening on April 19, highlighting the most innovative companies and bringing together the world’s most influential voices across media, entertainment and technology for the industry’s premier global event. As the only platform that convenes broadcasters, media companies, content creators and technology innovators at scale, NAB Show continues its century-long legacy as the catalyst for innovation, growth and deal-making in a rapidly evolving, multi-platform world. From artificial intelligence and the creator economy to sports, streaming and cloud transformation, NAB Show is where the tools, talent and ideas driving the future of storytelling converge. “NAB Show is where the global media ecosystem comes together not just to explore what’s next—but to build it,” said Karen
Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press release
A pioneer in smoke-free tobacco products, Philip Morris International is the only company that has received modified risk tobacco product authorizations for heated tobacco products.In their order, FDA concluded that: “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals” The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom